Literature DB >> 6767493

Diurnal variations in plasma diazepam concentrations associated with reciprocal changes in free fraction.

C A Naranjo, E M Sellers, H G Giles, J G Abel.   

Abstract

1 The characteristics and mechanism of fluctuations in diazepam and N-desmethyldiazepam concentrations and diazepam free fraction were studied in six volunteers, who received diazepam (10 mg, i.v. over 20 min) and in five chronic diazepam users. 2 Within a day total diazepam and N-desmethyldiazepam concentrations varied significantly (P less than 0.001) and were lower than predicted between 23.00 and 08.00 h and higher by 09.00 h. In contrast, diazepam free fraction also varied significantly (P less than 0.001) and was highest between 23.00 and 08.00 h and lower by 09.00 h. Coincident increases in total diazepam concentrations (P less than 0.005) and decreases in diazepam free fraction were associated with food intake (P less than 0.05). 3 The coincident diurnal variations in diazepam and N-desmethyldiazepam concentrations and the negative correlation between total diazepam concentration and diazepam free fraction (r = 0.73, P less than 0.001) suggest that the mechanism of the fluctuations is intravascular and tissue redistribution rather than effect on drug biotransformation. 4 These variations may introduce large between and within investigator experimental differences in the determination of kinetic parameters. Free drug concentration varies over the day, and within day variations in clinical effect may be observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767493      PMCID: PMC1429881          DOI: 10.1111/j.1365-2125.1980.tb04836.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Temporal variations in acetaminophen and phenacetin half-life in man.

Authors:  C A Shively; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Effect of food and repeated injections on serum diazepam levels.

Authors:  M Linnoila; K Korttila; M J Mattila
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-02

3.  Binding of diazoxide and other benzothiadiazines to human albumin.

Authors:  E M Sellers; J Koch-Weser
Journal:  Biochem Pharmacol       Date:  1974-02-01       Impact factor: 5.858

4.  Delayed recovery from a sedative: correlation of the plasma levels of diazepam with clinical effects after oral and intravenous administration.

Authors:  E S Baird; D M Hailey
Journal:  Br J Anaesth       Date:  1972-08       Impact factor: 9.166

5.  Pharmacokinetics of diazepam in dogs, mice and humans.

Authors:  E van der Klejin; J M van Rossum; E T Muskens; N V Rijntjes
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

6.  Blood level distribution patterns of diazepam and its major metabolite in man.

Authors:  J A De Silva; B A Koechlin; G Bader
Journal:  J Pharm Sci       Date:  1966-07       Impact factor: 3.534

Review 7.  Human circadian rhythms.

Authors:  J N Mills
Journal:  Physiol Rev       Date:  1966-01       Impact factor: 37.312

8.  Metabolism of diazepam in rat, dog, and man.

Authors:  M A Schwartz; B A Koechlin; E Postma; S Palmer; G Krol
Journal:  J Pharmacol Exp Ther       Date:  1965-09       Impact factor: 4.030

Review 9.  Circadian chronopharmacology.

Authors:  A Reinberg; F Halberg
Journal:  Annu Rev Pharmacol       Date:  1971       Impact factor: 13.820

10.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Authors:  U Klotz; G R Avant; A Hoyumpa; S Schenker; G R Wilkinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

View more
  13 in total

1.  Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding.

Authors:  J Feely; J Nadeau; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

2.  Fatty acids modulation of meal-induced variations in diazepam free fraction.

Authors:  C A Naranjo; E M Sellers; V Khouw
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

3.  Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.

Authors:  F J Rowell; S M Hui; A F Fairbairn; D Eccleston
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 4.  Time-dependence in benzodiazepine pharmacokinetics. Mechanisms and clinical significance.

Authors:  T W Guentert
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

5.  Diazepam plasma binding in the perinatal period: influence of nonesterified fatty acids.

Authors:  M J Ridd; K F Brown; R G Moore; W G McBride; R L Nation
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.

Authors:  H Nau; W Luck; W Kuhnz
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

7.  Disposition of intravenous diazepam in young men and women.

Authors:  H G Giles; E M Sellers; C A Naranjo; R C Frecker; D J Greenblatt
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins.

Authors:  R J Herman; A Chaudhary; C B Szakacs; D Woo; R Lane; M A Boctor
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Chronopharmacokinetics of acetaminophen in healthy human volunteers.

Authors:  J A Kolawole; P D Chuhwak; S O Okeniyi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.441

10.  Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

Authors:  G Storm; B Oosterhuis; F A Sollie; H W Visscher; W Sommer; H Beitinger; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.